Marcondes-Scalli Ana Carolina Aparecida, Rehder-Santos Patricia, Signini Étore De Favari, Castro Alex, Dato Carla, Furlan Leonardo, Liebano Richard Eloin, Catai Aparecida Maria
Cardiovascular Physical Therapy Laboratory, Nucleus of Research in Physical Exercise, Universidade Federal de São Carlos, São Carlos, Brazil.
Hospital de Ensino Dr. Washington Antônio de Barros, Petrolina, Brazil.
JMIR Res Protoc. 2025 Jul 11;14:e71829. doi: 10.2196/71829.
More than half of the world's population will be overweight or obese by 2035, and it is known that physical exercise, such as high-intensity interval training (HIIT), is a tool for controlling obesity by improving body composition and the metabolic profile. Noninvasive techniques such as therapeutic ultrasound (TUS) and the Aussie current have shown potential in controlling adipose tissue, but their effects combined with HIIT remain unknown. TUS may be combined with the Aussie current to potentiate the specific effects of each intervention, such as lipolysis induced by TUS and lymphatic activation promoted by the Aussie current. The integration of HIIT into this protocol is justified by its ability to stimulate β-oxidation and facilitate the metabolic use of fatty acids mobilized by the electrophysical resources. Furthermore, the use of HIIT as opposed to moderate-intensity continuous training contributes to reducing the total duration of the intervention.
This study aims to evaluate the effects of TUS+Aussie current combined with HIIT on body composition, serum metabolic profile, and cardiovascular autonomic modulation (CAM) in individuals with overweight and obesity.
This is a randomized, double-blind (researcher and outcome assessor) clinical study. The participants will be randomized into 3 groups: active TUS+Aussie current with HIIT group, placebo for TUS+Aussie current with HIIT group, and TUS+Aussie current-only group. All participants will undergo nutritional monitoring 30 days before the proposed interventions to adjust macronutrients, optimize energy intake, and improve diet quality. Primary outcomes include changes in subcutaneous adipose tissue thickness, body composition, and serum metabolic profile. Secondary outcomes assess perceived stress, body image, blood biochemistry, sleep quality, and CAM. Data analysis involves linear mixed models estimated using the maximum likelihood method with an appropriate covariance matrix structure.
A total of 60 participants will be recruited and randomized between February 2024 and June 2025. The baseline assessments and intervention are scheduled to be completed in August 2025, and data collection will be completed by the end of September 2025. Data acquisition is still ongoing; therefore, data analysis has not yet been carried out.
This is the first study to combine TUS+Aussie current with HIIT, potentially integrating the effects of lipolysis and fat oxidation and possible changes in the serum metabolic profile and CAM. The results could optimize treatment duration, promote changes in lipid profile, and maintain cardiovascular health in people with overweight and obesity.
Brazilian Registry of Clinical Trials RBR-4xh6232, Universal Trial Number: U1111-1287-2345; https://ensaiosclinicos.gov.br/rg/RBR-4xh6232.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/71829.
到2035年,全球超过一半的人口将超重或肥胖,众所周知,体育锻炼,如高强度间歇训练(HIIT),是通过改善身体成分和代谢状况来控制肥胖的一种手段。治疗性超声(TUS)和澳大利亚电流等非侵入性技术已显示出在控制脂肪组织方面的潜力,但它们与HIIT相结合的效果仍不清楚。TUS可与澳大利亚电流联合使用,以增强每种干预措施的特定效果,如TUS诱导的脂肪分解和澳大利亚电流促进的淋巴激活。将HIIT纳入该方案的合理性在于其能够刺激β-氧化并促进电物理资源动员的脂肪酸的代谢利用。此外,与中等强度连续训练相比,使用HIIT有助于缩短干预的总时长。
本研究旨在评估TUS+澳大利亚电流联合HIIT对超重和肥胖个体的身体成分、血清代谢状况及心血管自主神经调节(CAM)的影响。
这是一项随机、双盲(研究者和结果评估者)的临床研究。参与者将被随机分为3组:TUS+澳大利亚电流联合HIIT的活性组、TUS+澳大利亚电流联合HIIT的安慰剂组和仅TUS+澳大利亚电流组。所有参与者将在拟进行的干预前30天接受营养监测,以调整宏量营养素、优化能量摄入并改善饮食质量。主要结局包括皮下脂肪组织厚度、身体成分和血清代谢状况的变化。次要结局评估感知压力、身体形象、血液生化、睡眠质量和CAM。数据分析涉及使用具有适当协方差矩阵结构的最大似然法估计的线性混合模型。
总共将招募60名参与者,并于2024年2月至2025年6月期间进行随机分组。基线评估和干预计划于2025年8月完成,数据收集将于2025年9月底完成。数据采集仍在进行中;因此,尚未进行数据分析。
这是第一项将TUS+澳大利亚电流与HIIT相结合的研究,可能整合脂肪分解和脂肪氧化的效果以及血清代谢状况和CAM的可能变化。研究结果可能会优化治疗时长,促进血脂变化,并维持超重和肥胖人群的心血管健康。
巴西临床试验注册中心RBR-4xh6232,通用试验编号:U1111-1287-2345;https://ensaiosclinicos.gov.br/rg/RBR-4xh6232。
国际注册报告识别码(IRRID):DERR1-10.2196/71829。